ライフサイエンスコーパス: Hib

1 Hib antibody levels were protective in >99% of those sur

2 Hib caused 67% (2/3) of the H. influenzae meningitis iso

3 Hib conjugated to the carrier proteins CRM(197) and teta

4 Hib disease can be almost completely eliminated through

5 Hib IgG was associated with age at third immunization (P

6 Hib immunization was introduced in Kenyan infants in 200

7 Hib-CRM(197) induced a rapid increase in CRM(197)-specif

8 Hib-CRM(197) induced PS and CRM(197) antibodies, vigorou

9 Hib-meningococcal outer membrane protein complex (OMPC)

10 Hib-OMPC is unique among glycoconjugate vaccines by enga

11 Hib-OMPC was significantly less immunogenic in TLR2 KO m

12 effect on Hib immunogenicity of combining 2 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) wi

13 ifBC genes were detected in 109 of 170 (64%) Hib strains and in 46 of 162 (28%) NTHi isolates (P = 0.

14 TP/Hib and 7VPnC (group 2), or DTP and 7VPnC/Hib (group 3) at ages 2, 3 and 4 months.

15 ng either A2 or A18 L chains isolated from a Hib PS-vaccinated adult.

16 B cells were measured before a booster of a Hib-serogroup C meningococcal (MenC) conjugate vaccine a

17 ion against Hib disease wane over time after Hib vaccination at 2, 3, and 4 months of age without a b

18 ibody levels and clinical protection against Hib disease wane over time after Hib vaccination at 2, 3

19 introduction of an efficient vaccine against Hib.

20 In children aged <5 years of age, Hib incidence was 0.06 per 100 000 (2 cases), compared w

21 /294], 1.1% [1/88], and 22.2% [58/261]), and Hib (0.3% [1/294], 11.4% [10/88], and 14.9% [39/261]).

22 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) with diphtheria-TT-acellular pertussis (DTaP)(

23 degradation mediated by both Slimb-Cul1 and Hib-Cul3 E3 ligases.

24 n immunodeficiency virus (HIV) infection and Hib vaccination status were determined for children with

25 nt serum antibody responses against MenC and Hib could be elicited by inl immunization in combination

26 umoniae, nontyphoidal salmonellae (NTS), and Hib were the most frequently isolated pathogens, and hav

27 We found that OMPC and Hib-OMPC engaged human Toll-like receptor 2 (TLR2) expre

28 With the success of pneumococcal and Hib conjugate vaccines in reducing the risk of meningiti

29 alculated with the ratio of pneumococcal and Hib meningitis case fatality to pneumococcal and Hib men

30 meningitis case fatality to pneumococcal and Hib meningitis NPNM case fatality.

31 Pneumococcal and Hib morbidity due to non-pneumonia, non-meningitis (NPNM

32 Pneumococcal and Hib mortality have declined in children aged 1-59 months

33 monia cases attributable to pneumococcus and Hib was ascertained with vaccine clinical trial data and

34 onia deaths attributable to pneumococcus and Hib.

35 zone for N. meningitidis, S. pneumoniae and Hib were achieved within 1h.

36 Polyribitolribosyl phosphate (PRP) and Hib conjugate (PRP-T) vaccine given as a booster during

37 psule typing was more accurate than SAST and Hib-minus variants were rare.

38 ective thresholds; antibodies to tetanus and Hib were higher.

39 tibody levels in children aged <5 years, and Hib vaccine coverage and timing in children aged 1 to <2

40 compared with two or three doses of another Hib vaccine (conditional odds ratio 6.77 [95% CI 3.26-14

41 All A2 anti-Hib PS Abs sequenced to date possess a 10-amino acid L c

42 The low affinity anti-Hib PS mAbs of infants immunized with Hib oligosaccharid

43 variable region gene sequences encoding anti-Hib PS mAbs of infants immunized with Hib oligosaccharid

44 For anti-Hib antibodies, 4 of 14 (29%) and 5 of 6 (83%), respecti

45 tand these age-related changes in human anti-Hib PS immune responses we determined the variable regio

46 IgA anti-Hib antibody was also lower in the asplenic group, as wa

47 en exposure even in those with very low anti-Hib-PS antibody.

48 For infants with <1 microgram/mL anti-Hib-PS IgG antibody, mean AI rose by the time of preboos

49 ination were followed by high postboost anti-Hib-PS IgG antibody levels and avidity.

50 ages 2, 3, and 4 months showed reduced anti-Hib polysaccharide IgG (geometric mean concentration [GM

51 The anti-Hib avidity index postvaccination strongly correlated wi

52 The anti-Hib PS repertoire of children differs from that of adult

53 inct immunologic characteristics of the anti-Hib PS responses in young children immunized with other

54 wer in the asplenic group, as was total anti-Hib antibody measured by RIA.

55 ne or with Hib and DTaP-based vaccines; anti-Hib capsular polysaccharide IgG, poly-ribosyl-ribitol-ph

56 In a cohort with anti-Hib IgG <1.0 microg/mL following primary immunization, a

57 Avidity differed between infants with anti-Hib-PS IgG antibody <1 or >1 microg/mL postprimary serie

58 of TLR2 by Hib-OMPC was MyD88 dependent, as Hib-OMPC-induced TNF production was ablated in MyD88 kno

59 repertoire to the Haemophilus influenzae b (Hib) polysaccharide (PS).

60 zed with DTaP5/IPV/Haemophilus influenzae b (Hib-TT) vaccine at 2-3-4 months, 13-valent pneumococcal

61 mophilus influenzae strains, one serotype b (Hib) and two nonencapsulated b capsule-negative variants

62 on of the Haemophilus influenzae serotype b (Hib) conjugate vaccine into national immunization has le

63 he introduction of H. influenzae serotype b (Hib) conjugate vaccines.

64 Of 9 cases of H. influenzae, 8 were type b (Hib) and 1 was type f.

65 ne containing Haemophilus influenzae type b (Hib) and group C meningococcal polysaccharides, as well

66 ng clinical isolates of encapsulated type b (Hib) and nonencapsulated (NTHi) H. influenzae.

67 Encapsulated H. influenzae type b (Hib) and type f (Hif) are the most common serotypes asso

68 oliferated to Haemophilus influenzae type b (Hib) antigen.

69 umoniae), and Haemophilus influenzae type b (Hib) are three most common pathogens accounting for most

70 neumoniae and Haemophilus influenzae type b (Hib) between 2000 and 2015.

71 Haemophilus influenzae type b (Hib) capsular polysaccharide (PS) induces protective ant

72 ponses to the Haemophilus influenzae type b (Hib) component of acellular pertussis-containing combina

73 us (IPV), and Haemophilus influenzae type b (Hib) conjugate vaccine (DTaP-IPV-Hib) among children wit

74 90s, when the Haemophilus influenzae type b (Hib) conjugate vaccine for infants was introduced.

75 Haemophilus influenzae type b (Hib) conjugate vaccine is not perceived as a public heal

76 October 1992, Haemophilus influenzae type b (Hib) conjugate vaccine was introduced to infants in the

77 Haemophilus influenzae type b (Hib) conjugate vaccine, delivered as a three-dose series

78 nogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines and the effect on Hib immunogeni

79 spread use of Haemophilus influenzae type b (Hib) conjugate vaccines has nearly eradicated invasive H

80 aride (PS) of Haemophilus influenzae type b (Hib) covalently linked to carrier proteins, unlike pure

81 e of invasive Haemophilus influenzae type b (Hib) disease has significantly decreased since the intro

82 r of cases of Haemophilus influenzae type b (Hib) disease in the UK has risen.

83 ement of anti-Haemophilus influenzae type b (Hib) IgG avidity.

84 Haemophilus influenzae type b (Hib) invasive disease and oropharyngeal carriage continu

85 Haemophilus influenzae type b (Hib) is a leading cause of childhood bacterial meningiti

86 dy avidity to Haemophilus influenzae type b (Hib) polysaccharide (PS) was assessed in infants vaccina

87 ve shown that Haemophilus influenzae type b (Hib) polysaccharide conjugate vaccines can reduce nasoph

88 mmunized with Haemophilus influenzae type b (Hib) PS conjugate vaccine varies with age and Ag formula

89 to compare the genome of a virulent type b (Hib) strain with that of the laboratory-passaged Rd KW20

90 troduction of Haemophilus influenzae type b (Hib) vaccination and the rollout of antiretroviral thera

91 troduction of Haemophilus influenzae type b (Hib) vaccination of children has led to a decline in inc

92 schedule for Haemophilus influenzae type b (Hib) vaccination of infants in the United Kingdom consis

93 Haemophilus influenzae type b (Hib) vaccine and the 13-valent pneumococcal conjugate va

94 icacy of the conjugate H. influenzae type b (Hib) vaccine was the misidentification of isolates as se

95 uce conjugate Haemophilus influenzae type b (Hib) vaccine, which, as in other developing countries bu

96 accharide and Haemophilus influenzae type b (Hib) vaccines in ITP patients.

97 H. influenzae type b (Hib) was historically responsible for the majority of in

98 ction against Haemophilus influenzae type b (Hib), a rapidly invading encapsulated bacteria, is depen

99 me), invasive Haemophilus influenzae type b (Hib), acute hepatitis B, hepatitis A, varicella, Strepto

100 pneumococcal, Haemophilus influenzae type b (Hib), and meningococcal vaccines.

101 xtracted from Haemophilus influenzae type b (Hib), and the corresponding glycoconjugate made by conju

102 C (MenC) and Haemophilus influenzae type B (Hib), both of which are conjugated to the nontoxic mutan

103 otect against Haemophilus influenzae type b (Hib), serogroup C Neisseria meningitidis, and multiple c

104 ive bacterium Haemophilus influenzae type b (Hib).

105 80 including hepatitis A, acute hepatitis B, Hib, and varicella.

106 Structural differences between Hib pili and P-pili suggest a difference in the strategi

107 The ability to bind Hib PS resided exclusively with those Fab fragments havi

108 n following infant (with or without booster) Hib vaccination.

109 for the burden of invasive disease caused by Hib and other H. influenzae serotypes.

110 eumonia cases and pneumonia deaths caused by Hib.

111 b to the human nasopharynx is facilitated by Hib pili, filaments expressed on the bacterial surface.

112 Engagement of TLR2 by Hib-OMPC was MyD88 dependent, as Hib-OMPC-induced TNF pr

113 nd A18, only A2 contributes to the canonical Hib PS paratope.

114 Twenty-four invasive and 42 carriage Hib isolates, collected during 1992-1997, were character

115 ncentration and the frequency of circulating Hib-specific memory B cells were measured before a boost

116 urface exposed and was found in all clinical Hib and Hif isolates tested.

117 However, combining Hib-TT-B with DTaP(5)/IPV did not reduce the anti-PRP an

118 on was obtained for all laboratory-confirmed Hib cases diagnosed during 2009-2012.

119 ical characteristics of laboratory-confirmed Hib cases diagnosed during 2009-2012.

120 Conjugate Hib vaccine was delivered on time in a 3-dose primary se

121 in older children; and coverage of conjugate Hib vaccination was high (91% having 3 doses at 1-2 year

122 ion immunity after introduction of conjugate Hib vaccine in infancy without a booster dose in Kenya.

123 Introduction of conjugate Hib vaccine within the routine childhood immunization pr

124 he vaccine is made by chemically conjugating Hib capsular polysaccharide to the outer membrane protei

125 In many countries, Hib vaccine booster doses have been implemented after in

126 econd year of life on the basis of declining Hib antibody concentrations after the primary series.

127 t Hib vaccine program, perhaps by decreasing Hib carriage in child reservoirs.

128 encapsulated by SAST were capsule-deficient Hib variants (Hib-minus).

129 patients in the rituximab group demonstrated Hib killing (2 of 14 [14%], 5 of 6 [83%], P < .05).

130 or this conserved Arg residue in determining Hib PS-binding affinity.

131 In 1996, after switching to a different Hib conjugate vaccine, DTP-HbOC (which combines diphther

132 A DTaP-Hib vaccine evaluated in infants vaccinated at ages 2, 3

133 doses of their infant primary course as DTaP-Hib, compared with two or three doses of another Hib vac

134 ertussis-Haemophilus influenzae type b (DTaP-Hib) conjugate vaccines, 105 infants born at <32 weeks'

135 Despite reduced immunogenicity, DTaP-Hib combination vaccines appear to prime for immunologic

136 cines that contain acellular pertussis (DTaP-Hib).

137 tussis-containing combination vaccines (DTaP-Hib) is unclear.

138 us influenzae type b (DTP/Hib; group 1), DTP/Hib and 7VPnC (group 2), or DTP and 7VPnC/Hib (group 3)

139 pertussis/Haemophilus influenzae type b (DTP/Hib; group 1), DTP/Hib and 7VPnC (group 2), or DTP and 7

140 In industrialized countries with established Hib vaccination programs, however, little is known about

141 es of pneumonia cases and deaths to estimate Hib pneumonia burden.

142 to contribute to the repertoire, we examined Hib PS binding to a series of recombinant Fab fragments

143 l infection and 13 (UR 8-18) per 100 000 for Hib.

144 Abs with high affinity for Hib PS from infants, like most mAbs from adults, react o

145 of mAbs from children have high affinity for Hib PS, and the overall variable region gene repertoire

146 As with the recently published finding for Hib-TT complexes, it is the carbohydrate component that

147 pecific BCR sequences have been reported for Hib and TT, which made a vaccine containing these two Ag

148 or had not, respectively, received a fourth Hib conjugate vaccine dose (mean age, 3.9 years).

149 ldren and in those who had received a fourth Hib dose.

150 Amino acid sequence analysis of pilins from Hib pili and from P-pili expressed on uropathogenic Esch

151 105 infants born at <32 weeks' gestation had Hib IgG geometric mean concentrations (GMCs) and MCC ser

152 Premature infants had Hib GMCs of 0.27 microg/mL, with 21% achieving GMCs >1.0

153 nus-whole cell pertussis vaccines with HbOC [Hib oligosaccharide CRM197]), cases of invasive Hib dise

154 Importantly, Hib and Hif resistance against the bactericidal effect o

155 ococcal deaths and an 81% (59-91) decline in Hib deaths.

156 2A, hmwC, and hia genes were not detected in Hib strains.

157 cal studies of mechanisms of interference in Hib/DTaP vaccines.

158 eletion of the gene encoding for PH (lph) in Hib and Hif significantly reduced the interaction betwee

159 decreased after the initiation of an infant Hib vaccine program, perhaps by decreasing Hib carriage

160 (P=.03) after initiation of statewide infant Hib vaccination programs in 1991.

161 Invasive Hib disease in England and Wales has been declining sinc

162 Invasive Hib disease is no longer a major cause of acute bacteria

163 known about individuals who develop invasive Hib disease.

164 gate vaccines has nearly eradicated invasive Hib disease where the vaccines are used.

165 nd microbiological surveillance for invasive Hib disease (primarily meningitis) in the Western Region

166 NTS: Culture-based surveillance for invasive Hib disease at Kilifi District Hospital from 2000 throug

167 to rapid and sustained declines in invasive Hib disease incidence across all age groups.

168 An increase in invasive Hib disease incidence in the UK has coincided with the d

169 an 5 years, the annual incidence of invasive Hib disease 1 year before and 1 and 3 years after vaccin

170 Initially, the rate of invasive Hib disease decreased dramatically but has been increasi

171 study describes the epidemiology of invasive Hib disease in England and Wales during 2000-2012 and th

172 s enhanced national surveillance of invasive Hib disease in England and Wales.

173 oligosaccharide CRM197]), cases of invasive Hib disease increased, suggesting ongoing Hib transmissi

174 ylaxis, Guillain-Barre syndrome, or invasive Hib disease.

175 e extremely effective in preventing invasive Hib disease in infants and young children.

176 the carriers and caused 80% of the invasive Hib disease that occurred during April 1996-March 1997.

177 person-years) vs the third dose of DTaP-IPV-Hib (rate, 12.4 per 100 person-years) as the most recent

178 equently received the third dose of DTaP-IPV-Hib (rate, 12.8 per 100 person-years) after MMR, the IRR

179 son-years) after the second dose of DTaP-IPV-Hib (rate, 15.1 per 100 person-years).

180 tchemotherapy participants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13)

181 receipt of live MMR vs inactivated DTaP-IPV-Hib as the most recent vaccine was associated with a low

182 ection, comparing receipt of MMR vs DTaP-IPV-Hib as the most recent vaccine.

183 the alternating limb group received DTaP-IPV-Hib in the left leg at 2 months and in the right leg at

184 DTaP-IPV-Hib vaccination was associated with an increased risk of

185 mong 1- to 2-year-olds who received DTaP-IPV-Hib vaccine versus historical comparators (relative risk

186 sed risk was detected among 149,337 DTaP-IPV-Hib vaccinees versus historical comparators for any outc

187 tember 2008-January 2011 to compare DTaP-IPV-Hib vaccinees with historical recipients of other DTaP-c

188 Vaccination with DTaP-IPV-Hib was not associated with an increased risk of epileps

189 and Haemophilus influenzae type b (DTaP-IPV-Hib) administered at ages 3, 5, and 12 months and MMR at

190 zae type b (Hib) conjugate vaccine (DTaP-IPV-Hib) among children within the Vaccine Safety Datalink p

191 and Haemophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vacci

192 influenzae type b combined vaccine (DTaP-IPV-Hib) at 2, 3, and 4 months of age, and the pneumococcal

193 irus-Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine since September 2002.

194 eceived MMR after the third dose of DTaP-IPV-Hib, MMR (rate, 8.9 per 100 person-years) vs the third d

195 Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well tolerated

196 cine repertoire identified a number of known Hib-specific sequences but only one previously described

197 immunogenic in TLR2 KO mice, inducing lower Hib PS IgG and IgM titers compared with those in wild-ty

198 e every year from 2009 to 2012, and measured Hib antibody concentrations in five cross-sectional samp

199 th no junctional residue showed little or no Hib PS binding.

200 accines by engaging TLR2, and the ability of Hib-OMPC to elicit protective levels of Abs after one do

201 ict the effect of combined administration of Hib and DTaP vaccines on Hib immunogenicity and would be

202 ifE of strain Eagan inhibited the binding of Hib to human erythrocytes but did not inhibit the bindin

203 countries include a fourth dose (booster) of Hib vaccine in the second year of life on the basis of d

204 Global burden of Hib disease is substantial and almost entirely vaccine p

205 3 and December 2001, a total of 443 cases of Hib infection occurred in children eligible for vaccinat

206 However, the cases of Hib were either in unvaccinated individuals or children

207 Control of Hib disease in England and Wales is currently the best t

208 vaccination program enhanced the control of Hib infection in England and Wales.

209 , however, suggesting that a booster dose of Hib vaccine following infant vaccination is not essentia

210 ars following infant priming with 3 doses of Hib conjugate vaccine, anti-PRP IgG geometric mean conce

211 bution, syndrome distribution, and effect of Hib vaccine.

212 sons for this increase, the effectiveness of Hib conjugate vaccine was estimated by use of the screen

213 ity data were used for national estimates of Hib meningitis and non-pneumonia, non-meningitis disease

214 There is evidence of Hib disease among children in Cameroon, which warrants f

215 capsulated strains and the high frequency of Hib in countries without vaccination programs, there is

216 ly correlated with the relative frequency of Hib-specific sequences, indicating that the postvaccinat

217 hildren has led to a decline in incidence of Hib disease in young Alaskan children.

218 The incidence of Hib meningitis remained low (averaging 1.3 per 100 000 c

219 adults, coinciding with the introduction of Hib vaccination.

220 .001) and coincided with the introduction of Hib vaccination.

221 In Kenya, introduction of Hib vaccine into the routine childhood immunization prog

222 Continued monitoring of Hib carriage may provide insights into the epidemiology

223 elop estimates of incidence and mortality of Hib meningitis and serious non-pneumonia, non-meningitis

224 (1100 [700-1500]) had the highest numbers of Hib deaths in 2015.

225 haryngeal carriage is low and the profile of Hib antibodies suggests that protection wanes only after

226 cines have contributed to increased rates of Hib infection.

227 Kenya, use of a three-dose primary series of Hib vaccine without a booster dose has resulted in a sig

228 007 to 2010 was complemented with studies of Hib carriage in children aged 1 to <2 years, Hib antibod

229 omprehensive literature search of studies of Hib disease incidence, case-fatality ratios, age distrib

230 Expanded use of Hib vaccine could reduce childhood pneumonia and meningi

231 Conjugate vaccines of Hib PS linked to proteins, such as CRM(197), increase th

232 ic health priority in Africa because data on Hib disease burden and vaccine effectiveness are scarce.

233 b (Hib) conjugate vaccines and the effect on Hib immunogenicity of combining 2 Hib vaccines (Hib-teta

234 d administration of Hib and DTaP vaccines on Hib immunogenicity and would be suitable for preclinical

235 ve Hib disease increased, suggesting ongoing Hib transmission despite widespread vaccination.

236 either PsA-TT, one-fifth dose of PsACWY, or Hib-TT.

237 E of strain Eagan also bound to all piliated Hib strains but did not bind to the piliated NTHI strain

238 nti-Haemophilus influenzae b polysaccharide (Hib PS) antibodies elicited in elderly subjects followin

239 aemophilus influenzae type b polysaccharide (Hib PS).

240 Higher baseline and post-Hib-MenC booster responses (anti-PRP IgG and memory B ce

241 utine childhood immunization program reduced Hib disease incidence among children younger than 5 year

242 ic in infants and have significantly reduced Hib infections in the United States, but require multipl

243 n achieved since the introduction of routine Hib vaccination in 1992.

244 After the introduction of the routine Hib conjugate vaccination programme for infants, median

245 pared with 35.5 per 100 000 prior to routine Hib vaccination.

246 Spontaneous Hib-PS antibody rises after primary series DTaP-PRP-T-HB

247 to the nasopharynx, where the three-stranded Hib pilus filaments provide a robust tether to withstand

248 Sustained Hib conjugate vaccine-induced immunity in children is de

249 fimbriae 2 + 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were compared to responses

250 We calculated that Hib caused about 8.13 million serious illnesses worldwid

251 We estimated that Hib caused 371,000 deaths (247,000-527,000) in children

252 of electron micrograph images, we show that Hib pili comprise a helix 70 A in diameter with threefol

253 The Hib pilus filament has 3.0 subunits per turn, with each

254 The Hib-associated case fatality rate was 9.4% (10/106 cases

255 logically and structurally similar among the Hib strains but vary among the NTHI strains.

256 children aged <5 years annually), as did the Hib oropharyngeal carriage rate (0.9%).

257 to 1086327) and found to be the same for the Hib and two Hib(-) strains as well as some other encapsu

258 immunogenic region of the HifA pilin in the Hib pilus structure.

259 ssociated with reduced immunogenicity of the Hib component, although there is little agreement on the

260 d by shifts in the major VL component of the Hib PS-specific repertoire or by diminution of the prote

261 l conjugate vaccine and sustained use of the Hib vaccine could help accelerate achievement of child s

262 Introduction of the Hib vaccine in several states corresponded with a more r

263 ith the DTaP vaccine used in this study, the Hib GMC of premature infants was extremely low.

264 This Hib population was highly clonal, since only 2 strains,

265 Antibody concentrations to Hib and pneumococcal serotypes 14 and 18C were measured

266 However, in contrast to Hib, infections caused by H. influenzae serotype f (Hif)

267 times their original length, while damage to Hib pili occurs by slight shearing of subunits with resp

268 odies than unexposed infants (n = 54) did to Hib (0.37 [interquartile range {IQR}, 0.22-0.67] mg/L vs

269 le for CD1-restricted T cells in immunity to Hib.

270 = 46) had lower specific antibody levels to Hib (0.67 [IQR, 0.16-1.54] mg/L vs 1.34 [IQR, 0.15-4.82]

271 ntly lower IgM concentrations in response to Hib (P<.05) and to both pneumococcal serotypes 14 (P<.00

272 ociated with the increased susceptibility to Hib disease among individuals carrying the A2b allele.

273 on also proliferated to proteinase K-treated Hib antigen, suggesting that it recognized a nonpeptide.

274 and found to be the same for the Hib and two Hib(-) strains as well as some other encapsulated divisi

275 ccine formulations given to fully vaccinated Hib cases with those administered to fully immunised age

276 ningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administered in the left leg at 12 months.

277 ophilus influenzae type b conjugate vaccine (Hib-TT).

278 immunogenicity of combining 2 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) with diphtheria-

279 by SAST were capsule-deficient Hib variants (Hib-minus).

280 When Hib and Hif PH variants were separately expressed in non

281 duction in the antibody response to PRP when Hib-TT-A was administered in combination with DTaP(3) an

282 00-198 000) to 68 700 (44 600-86 000), while Hib deaths fell from 82 600 (52 300-112 000) to 15 600 (

283 vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccine and followed up to 43 and 72 month

284 vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccines, avidity increased in the period

285 Crowding was associated with Hib carriage.

286 n in morbidity and mortality associated with Hib infection.

287 Of 53 children with Hib admitted during 2002-2005, 29 (55%) were age-ineligi

288 ion status were determined for children with Hib disease admitted 2002-2005.

289 ntroduction, the median age of children with Hib was 8 months; case fatality was 23%.

290 h swabs taken, 46 (9.3%) were colonized with Hib.

291 nus-acellular pertussis (DTaP) combined with Hib-PS conjugated to tetanus toxoid (PRP-T) and hepatiti

292 y anti-Hib PS mAbs of infants immunized with Hib oligosaccharide-diphtheria toxin vaccine vaccine are

293 g anti-Hib PS mAbs of infants immunized with Hib oligosaccharide-diphtheria toxin vaccine.

294 cell response, 19 adults were immunized with Hib-CRM(197), and antibody titers, carrier protein-speci

295 like most mAbs from adults, react only with Hib PS and the structurally similar PS of Escherichia co

296 unized subcutaneously with Hib alone or with Hib and DTaP-based vaccines; anti-Hib capsular polysacch

297 influenzae (NTHi) isolates were probed with Hib cap-gene-containing plasmid pUO38 and with IS1016; a

298 Rats were immunized subcutaneously with Hib alone or with Hib and DTaP-based vaccines; anti-Hib

299 Vaccination with Hib conjugate vaccine PRP-OMP (polyribosylribitol phosph

300 Hib carriage in children aged 1 to <2 years, Hib antibody levels in children aged <5 years, and Hib v